| General information | Literature | Expression | Regulation | Mutation | Interaction |
Basic Information | |
|---|---|
Gene ID | 7434 |
Name | VIPR2 |
Synonymous | PACAP-R-3|PACAP-R3|SCZD16|VIP-R-2|VPAC2|VPAC2R|VPCAP2R;vasoactive intestinal peptide receptor 2;VIPR2;vasoactive intestinal peptide receptor 2 |
Definition | PACAP type III receptor|VIP and PACAP receptor 2|helodermin-preferring VIP receptor|pituitary adenylate cyclase-activating polypeptide type III receptor|vasoactive intestinal polypeptide receptor 2 |
Position | 7q36.3 |
Gene type | protein-coding |
Cancer type | Abstract |
| Ewing's sarcoma ;Bone | Vasoactive intestinal peptide (VIP) is a neuromodulator and growth regulator in the developing nervous system. We analyzed 10 primitive neuroectodermal tumor (PNET) cell lines, 29 central PNET (cPNET) and 17 tumors of the Ewing's sarcoma/peripheral PNET family (ESFT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern hybridization. Each of the 10 cell lines and 86.2% of cPNET expressed mRNA for VIP receptor 1 (VIPR1) compared to 52.9% of ESFT. VIPR2 was expressed in 75.8% of cPNET, in 28.6% of ESFT and in ALL 10 celllines. cPNET demonstrated high-affinity binding of 125I-VIP on quantitative autoradiography and in competitive binding assays. VIP inhibited tumor cell proliferation in a dose-dependent manner in 5 of 7 PNET cell lines. We conclude that VIPR1 and VIPR2 are highly expressed in cPNET and demonstrate that VIP is agrowth modulator in these tumors. |